1. Home
  2. HRZN vs ALLO Comparison

HRZN vs ALLO Comparison

Compare HRZN & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRZN
  • ALLO
  • Stock Information
  • Founded
  • HRZN 2008
  • ALLO 2017
  • Country
  • HRZN United States
  • ALLO United States
  • Employees
  • HRZN N/A
  • ALLO N/A
  • Industry
  • HRZN Finance/Investors Services
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HRZN Finance
  • ALLO Health Care
  • Exchange
  • HRZN Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • HRZN 251.0M
  • ALLO 252.9M
  • IPO Year
  • HRZN 2010
  • ALLO 2018
  • Fundamental
  • Price
  • HRZN $5.85
  • ALLO $1.23
  • Analyst Decision
  • HRZN Hold
  • ALLO Buy
  • Analyst Count
  • HRZN 4
  • ALLO 12
  • Target Price
  • HRZN $7.38
  • ALLO $8.80
  • AVG Volume (30 Days)
  • HRZN 719.9K
  • ALLO 3.1M
  • Earning Date
  • HRZN 10-28-2025
  • ALLO 11-06-2025
  • Dividend Yield
  • HRZN 22.56%
  • ALLO N/A
  • EPS Growth
  • HRZN N/A
  • ALLO N/A
  • EPS
  • HRZN N/A
  • ALLO N/A
  • Revenue
  • HRZN $97,144,000.00
  • ALLO N/A
  • Revenue This Year
  • HRZN N/A
  • ALLO N/A
  • Revenue Next Year
  • HRZN $9.61
  • ALLO $100.00
  • P/E Ratio
  • HRZN N/A
  • ALLO N/A
  • Revenue Growth
  • HRZN N/A
  • ALLO N/A
  • 52 Week Low
  • HRZN $5.71
  • ALLO $0.86
  • 52 Week High
  • HRZN $10.55
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • HRZN 32.27
  • ALLO 47.54
  • Support Level
  • HRZN $5.71
  • ALLO $1.29
  • Resistance Level
  • HRZN $6.20
  • ALLO $1.38
  • Average True Range (ATR)
  • HRZN 0.17
  • ALLO 0.10
  • MACD
  • HRZN 0.00
  • ALLO -0.01
  • Stochastic Oscillator
  • HRZN 20.87
  • ALLO 7.58

About HRZN Horizon Technology Finance Corporation

Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: